TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›KN
KN logo

KN

Knowles Corp

Next earnings Jul 22, 2026 · consensus $0.31 EPS, $162M rev

Last earnings +2.4% on 2026-04-23

Hold
$36.78
▼ -10.03%
$36.78▲ +104.67%
over 1Y
L $17.52H $42.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-10.0%
1W-9.8%
1M-6.2%
3M+42.2%
YTD+67.6%
1Y+104.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
C+
Valuation
Overvalued
Filings
Clean
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy

Genuine pivot to defense/medtech is working, but 80x P/E on 5.7% ROE leaves no margin for execution slip-ups.

Revenue $593M · FY2025

The read

Middling fundamentals and a rich price (~49% above fair value) leave little margin of safety — a wait-and-see.

Knowles is two years into a deliberate transformation into a 'premier industrial technology company' — the May 2025 investor day and the December 2024 divestiture of the Consumer MEMS Microphones business to Syntiant confirm management has decisively walked away from commodity consumer audio. The remaining PD (capacitors, RF filters) and MSA (balanced armature speakers, hearing-health microphones) segments target defense, medtech, industrial and electrification/energy — end markets with better margin structure and longer design cycles. The numbers corroborate the narrative: FY2025 revenue grew 7.2% to $593M, operating income jumped 35.7% to $70.3M, gross margin held a respectable 43.2%, and diluted EPS more than doubled to $0.50. The balance sheet is sound — long-term debt down 14.9% to $114M, no current debt, $776M equity — and management is shrinking the float, repurchasing $65M of stock (+21% YoY) while shares outstanding fell 3.1%.

But the price has run ahead of the operating story. At $40.15 the stock trades at 80x trailing diluted EPS and 5.7x sales for a business growing 7% with a 5.7% ROE and a 7.5% net margin. The five-year revenue track ($868M → $479M → $457M → $554M → $593M) shows the post-divestiture base is still well below the 2021 peak, and net income has whipsawed between +$150M and -$430M over the same window, with a -$569M accumulated deficit on the books to prove it. Cash fell 58.3% to $54.2M as buybacks and a 136% CapEx jump to $32.1M consumed liquidity — a defensible reinvestment if the medtech/defense thesis compounds, but a thin cushion if a customer concentration or China-tariff event hits.

Is KN a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Covered call~60d expiry
  • Long 100 shares @ ~36.78
  • Short call 39 @ ~2.49 est
debit $3,429max +$471max −$3,428BE 34.29

HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$868M$479M$457M$554M$593M
Gross profit$360M$227M$204M$235M$256M
Operating income$116M$90.8M$43.4M$51.8M$70.3M
Net income$150M-$430M$72.4M-$238M$44.2M
Diluted EPS$1.59-$4.63$0.79-$2.64$0.50
Net margin17.3%-89.8%15.8%-43.0%7.5%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$3.21B
EV / EBITDA30.1
EV / Sales5.4
EV / FCF—
P / FCF—
PEG (trailing)0.62
Earnings yield1.4%
FCF yield—

Quality & risk

ROIC (est.)6.2%
Free cash flow—
Total debt$114M
Net cash-$59.8M
Piotroski F-Score7/7

Capital returns

Buyback yield2.1%
Dividend yield (est.)—
Shareholder yield2.1%
Shares Δ YoY-3.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has been improving.
  1. 8-K Shareholder vote2026-04-29

    Annual meeting vote results (Item 5.07): director slate and routine proposals

  2. 10-Q Quarterly report2026-04-28

    Q1'26 10-Q: industrial-tech transformation progressing post-CMM divestiture

  3. 8-K Earnings results2026-04-23

    Q1'26 earnings release; continues post-divestiture margin recovery trend

  4. DEF 14A Proxy statement2026-03-11

    Proxy: routine director/say-on-pay vote; no governance red flags disclosed

  5. 8-K Officer / director change2026-02-20

    Executive officer change (5.02); leadership transition disclosed

  6. 10-K Annual report2026-02-09

    FY25 revenue $593M +7%, op income +36%, $65M buybacks; medtech/defense pivot

  7. 8-K Earnings results2026-02-05

    Q4'25 earnings: revenue $593M (+7%), EPS $0.50, net income more than doubled

  8. 10-Q Quarterly report2025-10-28

    Q3'25 10-Q showed improving margins from PD/MSA mix shift

  9. 8-K Earnings results2025-10-23

    Q3'25 earnings release; sustained YoY revenue and margin improvement

Recent filings

all on EDGAR ↗
4Period ending 2026-05-272026-05-29open ↗SDFiling2026-05-28open ↗144Filing2026-05-27open ↗4Period ending 2026-05-132026-05-14open ↗4Period ending 2026-05-052026-05-07open ↗144Filing2026-05-05open ↗144Filing2026-05-05open ↗144Filing2026-05-01open ↗4Period ending 2026-04-302026-04-30open ↗144Filing2026-04-30open ↗SCHEDULE 13GFiling2026-04-30open ↗4Period ending 2026-02-032026-04-29open ↗

Quality score

C+
ValueGrowthProfitHealthMom.
ValueF
GrowthA-
ProfitabilityC+
Financial healthA-
MomentumC+
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✗P/E below 25

Fair value est.

$18.68

Overvalued -49% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.50 × (8.5 + 1.5 × 22.0% growth) × 0.90 quality = 37.4× multiple. An estimate, not a price target.

17.5252-week42.80
Revenue
$593M
+7.2% YoY
Net margin
7.5%
ROE
5.7%
P/E
73.6

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$593M+7.2%
Net income$44.2M+118.6%
Gross profit$256M+9.2%
Operating income$70.3M+35.7%
Diluted EPS$0.50+118.9%
Cash & equivalents$54.2M-58.3%
Total assets$1.05B-6.0%
Stockholders' equity$776M+2.6%
Gross: 43.2%Op.: 11.9%

Frequently asked

Is Knowles Corp (KN) a buy?
KN currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Genuine pivot to defense/medtech is working, but 80x P/E on 5.7% ROE leaves no margin for execution slip-ups.
What is KN's fair value?
A Modified-Graham model based on KN's SEC fundamentals estimates a fair value of about $18.68. It is an estimate from reported earnings, not a price target.
Is KN overvalued or undervalued?
Against a Modified-Graham fair-value estimate, KN currently appears overvalued relative to its SEC-grounded earnings power.
What is Knowles Corp's quality score?
KN scores 64.37853463259762/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001587523, latest 10-Q filed 2026-04-28) · EODHD · Proprietary analysis · as of 6/25/2026, 1:34:55 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 9:34 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 4 sales

2026-05-27
Giesecke Daniel J.
Senior Vice President & COO
Sell10.2K @ $37.33$380K
2026-05-27
Giesecke Daniel J.
Senior Vice President & COO
Sell10.0K @ $37.31$374K
2026-05-13
Cabrera Raymond D.
SVP, Chief HR Officer
Exercise25.2K @ $16.77$423K
2026-05-13
Cabrera Raymond D.
SVP, Chief HR Officer
Tax17.6K @ $36.62$644K
2026-05-05
Niew Jeffrey
President & CEO
Exercise143K @ $16.77$2.40M
2026-05-05
Niew Jeffrey
President & CEO
Sell143K @ $33.25$4.75M
2026-04-30
Bastarrica Air A. Jr.
Vice President, Controller
Sell3.62K @ $30.91$112K
2026-04-28
Li Ye Jane
Director
Award6.26K @ $30.33$190K
2026-04-28
WISHART MICHAEL S
Director
Award6.26K @ $30.33$190K
2026-04-28
SHAVERS CHERYL L
Director
Award6.26K @ $30.33$190K
2026-04-28
Crowley Daniel J
Director
Award6.26K @ $30.33$190K
2026-02-03
Li Ye Jane
Director
Gift7.42K

Earnings history

beat/miss · move
2026-04-23Beat +10.4% est▲ +2.46%8-K ↗
2026-02-05Miss -0.9% est▲ +0.69%8-K ↗
2025-10-23Beat +4.2% est▲ +2.39%8-K ↗
2025-07-24Beat +0.2% est▲ +4.66%8-K ↗
2025-04-24—▲ +12.10%8-K ↗
2025-02-13—▼ -1.67%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Congressional trades

all activity →

Disclosed under the STOCK Act

2016-03-03Thomas MacArthurSell$1.00K–$15.0KPTR ↗
2016-02-06Thomas MacArthurBuy$1.00K–$15.0KPTR ↗
2016-01-06Thomas MacArthurSell$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score64 vs 67
Revenue growth7.2% vs 7.5%
Net margin7.5% vs 10.0%
Return on equity5.7% vs 12.0%
P/E73.6 vs 26.2